Your browser doesn't support javascript.
loading
Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 study.
Flisiak, R; Zarebska-Michaluk, D; Janczewska, E; Staniaszek, A; Gietka, A; Mazur, W; Tudrujek, M; Tomasiewicz, K; Belica-Wdowik, T; Baka-Cwierz, B; Dybowska, D; Halota, W; Lorenc, B; Sitko, M; Garlicki, A; Berak, H; Horban, A; Orlowska, I; Simon, K; Socha, L; Wawrzynowicz-Syczewska, M; Jaroszewicz, J; Deron, Z; Czauz-Andrzejuk, A; Citko, J; Krygier, R; Piekarska, A; Laurans, L; Dobracki, W; Bialkowska, J; Tronina, O; Pawlowska, M.
Afiliación
  • Flisiak R; Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
  • Zarebska-Michaluk D; Department of Infectious Diseases, Voivodship Hospital and Jan Kochanowski University, Kielce, Poland.
  • Janczewska E; Hepatology Outpatient Clinic, ID Clinic, Myslowice, Poland.
  • Staniaszek A; Department of Internal Medicine and Hepatology, Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland.
  • Gietka A; Department of Internal Medicine and Hepatology, Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland.
  • Mazur W; Clinical Department of Infectious Diseases, Specialist Hospital in Chorzów, Medical University of Silesia, Katowice, Poland.
  • Tudrujek M; Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin, Poland.
  • Tomasiewicz K; Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin, Poland.
  • Belica-Wdowik T; Regional Center for Diagnosis and Treatment of Viral Hepatitis and Hepatology, John Paul II Hospital, Kraków, Poland.
  • Baka-Cwierz B; Regional Center for Diagnosis and Treatment of Viral Hepatitis and Hepatology, John Paul II Hospital, Kraków, Poland.
  • Dybowska D; Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, Torun, Poland.
  • Halota W; Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, Torun, Poland.
  • Lorenc B; Pomeranian Center of Infectious Diseases, Department of Infectious Diseases, Medical University of Gdansk, Gdansk, Poland.
  • Sitko M; Department of Infectious and Tropical Diseases, Jagiellonian University Collegium Medicum, Kraków, Poland.
  • Garlicki A; Department of Infectious and Tropical Diseases, Jagiellonian University Collegium Medicum, Kraków, Poland.
  • Berak H; Hospital for Infectious Diseases in Warsaw, Medical University in Warsaw, Warsaw, Poland.
  • Horban A; Hospital for Infectious Diseases in Warsaw, Medical University in Warsaw, Warsaw, Poland.
  • Orlowska I; Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Warsaw, Poland.
  • Simon K; Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Warsaw, Poland.
  • Socha L; Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, Szczecin, Poland.
  • Wawrzynowicz-Syczewska M; Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, Szczecin, Poland.
  • Jaroszewicz J; Department of Infectious Diseases, Medical University of Silesia in Katowice, Bytom, Poland.
  • Deron Z; Ward of Infectious Diseases and Hepatology, Bieganski Regional Specialist Hospital, Lódz, Poland.
  • Czauz-Andrzejuk A; Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
  • Citko J; Medical Practice of Infections, Regional Hospital, Olsztyn, Poland.
  • Krygier R; Infectious Diseases and Hepatology Outpatient Clinic NZOZ "Gemini", Zychlin, Poland.
  • Piekarska A; Department of Infectious Diseases and Hepatology, Medical University of Lódz, Lódz, Poland.
  • Laurans L; Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, Szczecin, Poland.
  • Dobracki W; Multidisciplinary Regional Hospital in Gorzów Wielkopolski, Gorzów Wielkopolski, Poland.
  • Bialkowska J; MED-FIX Medical Center, Wroclaw, Poland.
  • Tronina O; Department of Infectious and Liver Diseases, Medical University of Lódz, Lódz, Poland.
  • Pawlowska M; Department of Transplantation Medicine, Nephrology, and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
J Viral Hepat ; 25(6): 661-669, 2018 06.
Article en En | MEDLINE | ID: mdl-29316039
The aim of the EpiTer-2 study was to analyse patient characteristics and their medication for HCV infection in Poland at the beginning of the interferon-free era. Analysis of data of HCV infected patients treated during the initial period of availability of interferon-free regimens in Poland, who started therapy after 1 July 2015 and had available an efficacy evaluation report before 30 June 2017 was undertaken. A total of 2879 patients with chronic hepatitis C were entered, including 46% with liver cirrhosis. The most common was genotype 1b (86.8%). The study population was gender balanced, the majority of patients were overweight or obese and 69% presented comorbidities, with the highest prevalence that for hypertension. More than half of patients were retreated due to failure of previous therapy with pegylated interferon and ribavirin. Almost two-third of patients received current therapy with ombitasvir/paritaprevir/ritonavir±dasabuvir (OPrD) ±ribavirin. Other patients received mostly sofosbuvir-based regimens including combination with ledipasvir and pegylated interferon and ribavirin for genotype 3-infected patients. Efficacy of treatment in the whole study population measured as intent-to-treat analysis was 95%. The most frequent regimen, administered for patients infected with genotype 1b, was 12 weeks of OPrD, resulting in an SVR rate of 98%. At least one adverse event was reported in 38% of patients, and the death rate was 0.8%. In conclusion, data from the EpiTer-2 study confirmed the excellent efficacy and safety profile of the real-world experience with recently introduced therapeutic options for genotype 1 HCV infection, but demonstrated weakness of the current therapeutic programme regarding genotype 3 infections.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Hepatitis C Crónica / Cirrosis Hepática Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Viral Hepat Asunto de la revista: GASTROENTEROLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Hepatitis C Crónica / Cirrosis Hepática Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Viral Hepat Asunto de la revista: GASTROENTEROLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Reino Unido